Feb 13, 2025
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
Jan 16, 2024
Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
Jan 03, 2024
CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
Jan 02, 2024
CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials
Jan 25, 2021
Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients
Jan 07, 2021
Lyfebulb Announces Call-to-Action for Submissions to the 2021 Innovation Challenge: Thriving with Transplantation
Nov 16, 2020
Urban League, CSL Behring Partner to Address Community Needs including Public Health, Workforce Diversity, Leadership Development
Nov 10, 2020
CSL Behring To Present New Real-World Data on Outcomes Following Acute Coronary Syndrome at the American Heart Association (AHA) Virtual Scientific Sessions 2020
Nov 05, 2020
CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patients
Nov 02, 2020
Orphan Drug Designation Granted for CSL Behring's Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease
Oct 29, 2020
CSL Named as One of the World's Best Employers
Oct 08, 2020
First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine
Sep 28, 2020
U.S. Food and Drug Administration Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients
Jul 30, 2020
At White House Roundtable, Plasma Industry Leader & CSL CEO Paul Perreault Urges People to Donate Plasma in the Fight Against COVID-19
Jul 09, 2020
CSL Behring Announces Professor Heimburger Awards in Advance of ISTH 2020 Virtual Congress
Jul 03, 2020
IDELVION® Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
Jun 24, 2020
CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure
Jun 19, 2020
Yi Deng and Bill Mezzanotte Elected to University City Science Center Board of Directors
Jun 12, 2020
CSL Behring to Attend and Sponsor World Federation of Hemophilia First Ever Virtual Summit
Jun 08, 2020
CSL Behring to Acquire Biotech Company Vitaeris